The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Mild immune-related toxicities linked to improved NSCLC outcomes
Diane Tseng, MD, PhD, Fred Hutch Cancer Center, Seattle, WA, discusses the complex relationship between toxicity and treatment outcomes in non-small cell lung cancer (NSCLC), highlighting an observation that patients experiencing mild immune adverse events, despite requiring treatment holds and steroids, tend to have improved outcomes compared to those without such toxicities. This suggests a unique association between certain toxicities and better outcomes, even in the face of treatment interruptions and immunosuppression. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think for these kinds of analyses, it’s really challenging to disentangle the relationship between what the contribution is of the toxicity itself from its treatment. Certainly, I think it’s very interesting that the patients who developed mild immune adverse events and where they did experience treatment holds as well as often steroids in their management still had improved outcomes compared to patients who did not experience immune adverse events, suggesting that there’s something special about those kinds of toxicities that are associated with improved outcomes despite those types of interruptions and immunosuppressive treatments...
I think for these kinds of analyses, it’s really challenging to disentangle the relationship between what the contribution is of the toxicity itself from its treatment. Certainly, I think it’s very interesting that the patients who developed mild immune adverse events and where they did experience treatment holds as well as often steroids in their management still had improved outcomes compared to patients who did not experience immune adverse events, suggesting that there’s something special about those kinds of toxicities that are associated with improved outcomes despite those types of interruptions and immunosuppressive treatments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
